All In Biotech

Drug Trial Radar · NCT07237256

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

No Chemotherapy in Intermediate-risk HR+ HER2- Early Breast Cancer Treated With Ribociclib (LEE-011) in the Adjuvant Setting, a Non-inferiority Phase III Trial

Last checked: Nov 20, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,902 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,902

Planned (sponsor's estimate)

Start

Dec 18, 2025

Primary completion

Nov 30, 2033

Study completion Dec 31, 2037

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis; SOLTI Breast Cancer Research Group; GBG Forschungs GmbH; Latin American Cooperative Oncology Group; Gruppo Italiano Mammella (GIM); BOOG Study Center; Canadian Cancer Trials Group; Swiss Cancer Institute; Menarini Silicon Biosystems, INC
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The advent of CDK4/6 inhibitors (drugs designed to block the action of CDK4/6 proteins, which play a key role in cell proliferation) has improved treatment prospects for patients with metastatic breast cancer whose tumour cells express hormone receptors but not the HER2 protein (HR+/HER2-). The NATALEE study showed that the addition of ribociclib for three years to conventional adjuvant hormone therapy (i.e. after surgery) prolonged survival free of invasive disease (i.e. extending to surrounding tissues) in patients with early HR breast cancer+ /HER2-. Unlike other studies, NATALEE included a group of patients at intermediate risk of recurrence, usually treated with adjuvant chemotherapy before receiving hormone therapy. However, the benefit of adjuvant chemotherapy in these patients is uncertain. The hypothesis of the NoLEEta study is that by using the CDK 4/6 inhibitor, patients could avoid adjuvant chemotherapy and therefore be spared the side-effects associated with this chemotherapy, without reducing the efficacy of the treatment.

Conditions

  • Breast Cancer

Interventions

  • Chemotherapy followed by endocrine therapy and ribociclib treatmentDrug

    Endocrine therapy and ribociclib treatment

  • De-escalationOther

    De-escalation of the chemotherapy in the adjuvant setting

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive breast cancer-free survival (iBCFS)Time frame: From ramdomization to iBCFS, up to 12 years.

Locations

138 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinique de l'Europe

    Amiens, France · Not yet recruiting

  • Institut de Cancérologie de l'Ouest - Site Paul Papin

    Angers, France · Not yet recruiting

  • CH Victor Dupouy

    Argenteuil, France · Not yet recruiting

  • CH Henri Mondor

    Aurillac, France · Active not recruiting

  • Centre Hospitalier d'Auxerre

    Auxerre, France · Not yet recruiting

  • Sainte Catherine - Institut du Cancer Avignon Provence

    Avignon, France · Recruiting

  • Centre Hospitalier de la Cote Basque

    Bayonne, France · Active not recruiting

  • Centre Hospitalier Simone Veil de Beauvais

    Beauvais, France · Active not recruiting

  • Centre Hospitalier Universitaire de Besancon

    Besançon, France · Not yet recruiting

  • Institut Bergonie

    Bordeaux, France · Not yet recruiting

  • Clinique Tivoli

    Bordeaux, France · Not yet recruiting

  • Centre Francois Baclesse

    Caen, France · Not yet recruiting

  • Centre Hospitalier de Carcassonne

    Carcassonne, France · Not yet recruiting

  • Centre Hospitalier William Morey

    Chalon-sur-Saône, France · Active not recruiting

  • Centre Hospitalier Métropole de Savoie

    Chambéry, France · Active not recruiting

  • Centre d'Oncologie et de Radiothérapie 37

    Chambray-lès-Tours, France · Not yet recruiting

  • CH Cholet

    Cholet, France · Not yet recruiting

  • Centre Jean Perrin

    Clermont-Ferrand, France · Not yet recruiting

  • Hospices Civils de Colmar

    Colmar, France · Active not recruiting

  • Polyclinique Saint Côme

    Compiègne, France · Not yet recruiting

  • Clinique de Flandre

    Coudekerque-Branche, France · Not yet recruiting

  • Institut de Cancérologie de Bourgogne

    Dijon, France · Not yet recruiting

  • CHI Fréjus St-Raphaël

    Fréjus, France · Active not recruiting

  • Polyclinique de Blois

    La Chaussée-Saint-Victor, France · Not yet recruiting

  • Centre Hospitalier Départemental de Vendée

    La Roche-sur-Yon, France · Not yet recruiting

  • CHU Grenoble

    La Tronche, France · Not yet recruiting

  • Centre Hospitalier de Versailles

    Le Chesnay, France · Not yet recruiting

  • Centre Hospitalier le Mans

    Le Mans, France · Not yet recruiting

  • Clinique Victor Hugo

    Le Mans, France · Not yet recruiting

  • Polyclinique de Limoges - Site Cinique Chénieux

    Limoges, France · Not yet recruiting

  • Centre Hospitalier Universitaire de Limoges

    Limoges, France · Active not recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Hôpital Privé Jean Mermoz

    Lyon, France · Active not recruiting

  • Institut Paoli Calmettes

    Marseille, France · Not yet recruiting

  • Centre Hospitalier Annecy Genevois

    Metz-Tessy, France · Not yet recruiting

  • Centre de Cancerologie du Grand Montpellier

    Montpellier, France · Recruiting

  • Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace (GHRMSA)

    Mulhouse, France · Recruiting

  • Hopital Privé du Confluent

    Nantes, France · Not yet recruiting

  • Centre Antoine Lacassagne

    Nice, France · Recruiting

  • CHU de NÎMES - Institut de Cancérologie du Gard

    Nîmes, France · Not yet recruiting

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.